Sangui BioTech International AAQS 2024

Sangui BioTech International AAQS

Ticker

SGBI

ISIN

US80105B1017

WKN

906757

Revenue Net Income P/E P/S EBIT Dividend Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE

Sangui BioTech International has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Sangui BioTech International in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

Sangui BioTech International Aktienanalyse

What does Sangui BioTech International do?

Sangui Biotech International Inc. is a biotechnology company based in the USA that focuses on the research and development of medical products. It was founded in 1994 by Dr. Joachim Fleing with the vision of developing a new type of blood substitute that could replace blood transfusions. The company's business model is centered around developing and marketing products that help combat blood diseases and make blood supply safer. They have different divisions focusing on various aspects of medical research and development, including the development of blood substitute products, wound and scar healing products, and products for individuals with stomas. The company also has a line of products for blood clotting. They strive to be a leader in the medical industry and have already achieved success with their innovative products, receiving patents and awards. They collaborate with other companies and research institutions worldwide to develop new products and exchange research findings. Overall, Sangui Biotech International Inc. is an innovative and emerging biotechnology company dedicated to developing medical products to improve people's health and save lives. Sangui BioTech International ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Frequently Asked Questions about Sangui BioTech International stock

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sangui BioTech International

Our stock analysis for Sangui BioTech International Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sangui BioTech International Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.